MOLN

Molecular Partners AG ADR (MOLN) | Rumor.io

Molecular Partners

MOLN

Attention (50-day avg)0%

Attention rank (50-day avg)#3,804

Bullish sentiment (50-day avg)100%

Price to earnings ratio1.71

Market capitalization147.9M

Earnings per share-1.63

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-61.7M

Social

What share of all stock conversation is about MOLN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 25

Molecular Partners AG (MOLN) has reported financial results and highlighted recent clinical pipeline progress for H1 2025.
The company's H1 2025 results will be released on August 25, along with several other earnings reports.
Molecular Partners will also be participating in the WCOG_AGW25 conference from August 25-27.

Generated by AI

Sentiment

Of the messages about MOLN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +28.57
Bearish	—	—	—	0% -28.57

Topics

Of the messages about MOLN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	89.02%
Analysts	—	—	0%	5.78%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.58%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	4.62%

Announcements· Apr 26

Molecular Partners $MOLN to regain global rights for MP0310 from Amgen, according to a recent announcement.
The company provided an update on its ensovibep program following Novartis' quarterly earnings call, highlighting the progress and implications of the partnership.
Molecular Partners $MOLN has regained global rights for its MP0310 program from Amgen, marking a significant development in the company's pipeline.

Controversies· Jul 27

A class action lawsuit has been filed on behalf of investors in Molecular Partners AG (MOLN) due to a significant loss in stock value.
The lawsuit alleges wrongdoing by the company and seeks to recover losses for affected investors.
Several law firms have issued statements encouraging investors to join the lawsuit, citing a deadline of September 12, 2022.

Generated by AI

Community

Of the messages about MOLN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	35.71%	39.6%
Newcomers	—	—	64.29%	60.4%

Regulars· Apr 27

Molecular Partners shares have declined significantly, with a 37% drop in premarket trading and a 38.1% decrease in share price, hitting a new 52-week low.
The decline is attributed to Credit Suisse downgrading Molecular Partners to Underperform from Neutral, and Amgen returning the global rights for tumor treatment candidate MP0310.
Molecular Partners is set to regain global rights for MP0310 from Amgen, a development that could potentially impact the company's future prospects.

Newcomers· Jun 18

New users are excited about Molecular Partners AG's (MOLN) potential upside, citing it as a promising stock for growth.
Some newcomers are discussing the company's pipeline and the progress of its clinical trials, highlighting the potential for breakthroughs.
There is a growing interest in Molecular Partners AG's (MOLN) stock analysis, with new users looking to understand the company's valuation and growth prospects.

Generated by AI

DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027CD70 selected as new radio target for the treatment of kidney cancer and other indications, with clinical program start anticipated in 2027Cash position of CHF 67.9 million (USD ~84 million) as of June 30, 2026, expected to fund operations into late 2027 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) --

1mo agoYahoo Finance

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacyPresentation outlines Radio-DARPins’ ability to match target and disease biology for improved outcomes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partne

2mo agoYahoo Finance

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Edgewise Therapeutics Inc (EWTX-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

H.C. Wainwright reiterates Molecular Partners stock rating on trial progress

2mo agoInvesting.com

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected in 2027Additional compassionate care work now initiated by the Nuclear Medicine Research Institute in South Africa utilizing 225Ac-loaded DLL3 Radio-DARPin, highlighting the versatility of DARPins as isotope agnostic vectorsFIH imaging for MP0726, Radio-DARPin targeting MSLN, plann

2mo agoYahoo Finance

Molecular Partners and Orano Med Dose First Patients in MP0712 Phase 1/2a Trial

Detailed price information for Molecular Partners Ag ADR (MOLN-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about MOLN also mention

#	Name	Attention
1	Novartis AG Sponsored ADRNVS	0%-0.01
2	AKYA - Akoya Biosciences, Inc.	——
3	Bowhead Specialty Holdings Inc.BOW	0%-0.01
4	LCNB Corp.LCNB	0%0
5	WAVS - Western Acquisition Ventures Corp.	——
6	IGMS - IGM Biosciences, Inc.	——
7	FNCH - Finch Therapeutics Group, Inc.	——
8	Airgain Inc.AIRG	0%new
9	LifeStance Health Group, Inc.LFST	0%0
10	TSRI - TSR, Inc.	——

Molecular Partners AG ADR

Healthcare
Biotechnology

Molecular Partners AG ADR is a clinical-stage biopharmaceutical company focused on designing and developing DARPin therapeutics, a proprietary protein-based platform used to create highly specific medicines. The company’s current work centers on therapies for oncology, immuno-oncology, ophthalmology, and other serious diseases, with programs spanning preclinical research and clinical trials. Its pipeline includes candidates designed to address solid tumors, blood cancers, retinal disorders, and other conditions where targeted protein engineering may offer therapeutic value. Molecular Partners AG ADR plays a specialized role in the biotechnology market by advancing novel biologic drug candidates and platform technologies for potential use in precision medicine. Headquartered in Schlieren, Switzerland, the company operates as a research-driven developer of innovative protein therapies for global healthcare applications.

Website

Location

Wagistrasse 14

Schlieren, 8952

Switzerland

Social

What share of all stock conversation is about MOLN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Aug 25

Molecular Partners AG (MOLN) has reported financial results and highlighted recent clinical pipeline progress for H1 2025.
The company's H1 2025 results will be released on August 25, along with several other earnings reports.
Molecular Partners will also be participating in the WCOG_AGW25 conference from August 25-27.

Generated by AI

Sentiment

Of the messages about MOLN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +28.57
Bearish	—	—	—	0% -28.57

Topics

Of the messages about MOLN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	89.02%
Analysts	—	—	0%	5.78%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.58%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	4.62%

Announcements· Apr 26

Molecular Partners $MOLN to regain global rights for MP0310 from Amgen, according to a recent announcement.
The company provided an update on its ensovibep program following Novartis' quarterly earnings call, highlighting the progress and implications of the partnership.
Molecular Partners $MOLN has regained global rights for its MP0310 program from Amgen, marking a significant development in the company's pipeline.

Controversies· Jul 27

A class action lawsuit has been filed on behalf of investors in Molecular Partners AG (MOLN) due to a significant loss in stock value.
The lawsuit alleges wrongdoing by the company and seeks to recover losses for affected investors.
Several law firms have issued statements encouraging investors to join the lawsuit, citing a deadline of September 12, 2022.

Generated by AI

Community

Of the messages about MOLN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	35.71%	39.6%
Newcomers	—	—	64.29%	60.4%

Regulars· Apr 27

Molecular Partners shares have declined significantly, with a 37% drop in premarket trading and a 38.1% decrease in share price, hitting a new 52-week low.
The decline is attributed to Credit Suisse downgrading Molecular Partners to Underperform from Neutral, and Amgen returning the global rights for tumor treatment candidate MP0310.
Molecular Partners is set to regain global rights for MP0310 from Amgen, a development that could potentially impact the company's future prospects.

Newcomers· Jun 18

New users are excited about Molecular Partners AG's (MOLN) potential upside, citing it as a promising stock for growth.
Some newcomers are discussing the company's pipeline and the progress of its clinical trials, highlighting the potential for breakthroughs.
There is a growing interest in Molecular Partners AG's (MOLN) stock analysis, with new users looking to understand the company's valuation and growth prospects.

Generated by AI

Molecular Partners

Social

Aug 25

Sentiment

Topics

Announcements· Apr 26

Controversies· Jul 27

Community

Regulars· Apr 27

Newcomers· Jun 18

News

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

Wall Street Analysts Are Bullish on Top Healthcare Picks

H.C. Wainwright reiterates Molecular Partners stock rating on trial progress

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

Molecular Partners and Orano Med Dose First Patients in MP0712 Phase 1/2a Trial

Also Discussed

Molecular Partners AG ADR

Company Information

Location

News

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

Wall Street Analysts Are Bullish on Top Healthcare Picks

H.C. Wainwright reiterates Molecular Partners stock rating on trial progress

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

Molecular Partners and Orano Med Dose First Patients in MP0712 Phase 1/2a Trial

Also Discussed

Social

Aug 25

Sentiment

Topics

Announcements· Apr 26

Controversies· Jul 27

Community

Regulars· Apr 27

Newcomers· Jun 18